1. Home
  2. CDLR vs GHRS Comparison

CDLR vs GHRS Comparison

Compare CDLR & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cadeler AS

CDLR

Cadeler AS

SELL

Current Price

$21.67

Market Cap

2.1B

Sector

N/A

ML Signal

SELL

Logo GH Research PLC

GHRS

GH Research PLC

HOLD

Current Price

$18.22

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDLR
GHRS
Founded
2008
2018
Country
Denmark
Ireland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.0B
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
CDLR
GHRS
Price
$21.67
$18.22
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
★ $42.89
AVG Volume (30 Days)
72.7K
★ 299.1K
Earning Date
11-23-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$54.35
N/A
Revenue Next Year
$37.14
N/A
P/E Ratio
$7.39
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.37
$12.04
52 Week High
$30.01
$31.44

Technical Indicators

Market Signals
Indicator
CDLR
GHRS
Relative Strength Index (RSI) 38.54 22.04
Support Level $20.96 $13.58
Resistance Level $22.21 $22.88
Average True Range (ATR) 0.49 1.19
MACD -0.05 -0.33
Stochastic Oscillator 47.73 2.31

Price Performance

Historical Comparison
CDLR
GHRS

About CDLR Cadeler AS

Cadeler AS is an offshore wind installation vessel contractor. It currently operates various offshore jack-up wind installation vessels, with new builds on order. The Group operates within the market for the transportation and installation of offshore wind turbine generators (WTGs) and their foundations. In addition to wind farm installation, its vessels can perform maintenance, decommissioning, and other general construction tasks within the offshore industry. Cadler's customer base consists of offshore wind farm developers, original equipment manufacturers, and various offshore contractors. Geographically, the Group generates maximum revenue from the United States and the rest from the United Kingdom, Taiwan, Germany, Denmark, Poland, and other regions.

About GHRS GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Share on Social Networks: